Erytech Pharma (France)

Recent papers from Erytech Pharma (France)

1. Predicting the Multi-Factor Trigger Probability of Major Urban Security Incidents Using the XGBoost Ensemble AlgorithmAdvanced Electromagnetics · 2026
2. Hapten-Based Cancer Immunotherapy: From Immune Activation to Antitumor ActivityCells · 2026
3. Abstract CT051: From preclinical models to first-in-human evaluation of STC-1010 immunotherapy in unresectable advanced colorectal cancerCancer Research · 2026
4. Abstract 2868: MaaT013 pooled fecal microbiotherapy improves gastrointestinal physiology and controls inflammation which delays GvHD in a proof-of-concept humanized mouse studyCancer Research · 2026
5. Long-Distance Trail Running Induces Inflammatory-Associated Protein, Lipid, and Purine Oxidation in Red Blood CellsBlood Red Cells & Iron · 2026
6. Abstract A061: First-in-human hapten-enhanced stressed-ghost cell immunotherapy (STC-1010) for advanced colorectal cancer: preclinical and early clinical dataCancer Immunology Research · 2026
7. TRYBECA-1: A Randomized Phase III Study of Eryaspase Combined With Chemotherapy Versus Chemotherapy as Second-Line Treatment in Patients With Advanced Pancreatic AdenocarcinomaJournal of Clinical Oncology · 2025
8. Bone status in patients with chronic hypoparathyroidism: results from the Italian HypoparaNET databaseAging Clinical and Experimental Research · 2025
9. Phase 1 clinical trial of eneboparatide, a novel PTH receptor 1 agonistEndocrine Connections · 2025
10. Gut microbiota restoration with oral pooled fecal microbiotherapy after intensive chemotherapy: the phase 1b CIMON trialBlood Advances · 2025
11. Focus on therapeutic peptides and their deliveryInternational Journal of Pharmaceutics · 2025
12. Skeletal health status among patients with chronic hypoparathyroidism: results from the Canadian National Hypoparathyroidism Registry (CNHR)Osteoporosis International · 2025
13. Stable Biotherapeutic Penetration Screening in Critically Small Colorectal Metastatic Cancer Biopsies Allows for Oncolytic Virus‐Delivered Chemotherapeutic Response Assessment through 3D Bioprinted Organoid ExpansionAdvanced Therapeutics · 2024
14. Safety comparison of single-donor and pooled fecal microbiota transfer product preparation in ulcerative colitis: systematic review and meta-analysisBMC Gastroenterology · 2024
15. Narrative Review: Advancing Dysbiosis Treatment in Onco-Hematology with Microbiome-Based Therapeutic ApproachMicroorganisms · 2024
16. 8406 A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZP-3813, a Novel Small Peptide Growth Hormone Receptor Antagonist, in Healthy SubjectsJournal of the Endocrine Society · 2024
17. 8749 Skeletal effects among pre and postmenopausal women with hypoparathyroidism (HypoPT); data from the Canadian National Hypoparathyroidism Registry (CNHR)Journal of the Endocrine Society · 2024
18. 7145 Enhanced Ability of the Small Peptide GH Receptor Antagonist, AZP-3813, to Decrease IGF1 When Combined with the Somatostatin Analog, OctreotideJournal of the Endocrine Society · 2024
19. 8041 Eneboparatide, A Potent Stimulator Of Urinary Calcium Reabsorption, Induces Prolonged Renal Cortex Retention And PTH1 Receptor SignalingJournal of the Endocrine Society · 2024
20. 7773 Increased Fragility of Bone Over Timein Female Patients with Chronic Hypoparathyroidism: Real-world Data from the Italian CohortJournal of the Endocrine Society · 2024